Show simple item record

dc.contributor.authorMerker, JDen_US
dc.contributor.authorOxnard, GRen_US
dc.contributor.authorCompton, Cen_US
dc.contributor.authorDiehn, Men_US
dc.contributor.authorHurley, Pen_US
dc.contributor.authorLazar, AJen_US
dc.contributor.authorLindeman, Nen_US
dc.contributor.authorLockwood, CMen_US
dc.contributor.authorRai, AJen_US
dc.contributor.authorSchilsky, RLen_US
dc.contributor.authorTsimberidou, AMen_US
dc.contributor.authorVasalos, Pen_US
dc.contributor.authorBillman, BLen_US
dc.contributor.authorOliver, TKen_US
dc.contributor.authorBruinooge, SSen_US
dc.contributor.authorHayes, DFen_US
dc.contributor.authorTurner, NCen_US
dc.date.accessioned2018-05-22T14:47:49Z
dc.date.issued2018-06en_US
dc.identifier.citationJournal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018, 36 (16), pp. 1631 - 1641en_US
dc.identifier.issn0732-183Xen_US
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/1684
dc.identifier.eissn1527-7755en_US
dc.identifier.doi10.1200/jco.2017.76.8671en_US
dc.description.abstractPurpose Clinical use of analytical tests to assess genomic variants in circulating tumor DNA (ctDNA) is increasing. This joint review from ASCO and the College of American Pathologists summarizes current information about clinical ctDNA assays and provides a framework for future research. Methods An Expert Panel conducted a literature review on the use of ctDNA assays for solid tumors, including pre-analytical variables, analytical validity, interpretation and reporting, and clinical validity and utility. Results The literature search identified 1,338 references. Of those, 390, plus 31 references supplied by the Expert Panel, were selected for full-text review. There were 77 articles selected for inclusion. Conclusion The evidence indicates that testing for ctDNA is optimally performed on plasma collected in cell stabilization or EDTA tubes, with EDTA tubes processed within 6 hours of collection. Some ctDNA assays have demonstrated clinical validity and utility with certain types of advanced cancer; however, there is insufficient evidence of clinical validity and utility for the majority of ctDNA assays in advanced cancer. Evidence shows discordance between the results of ctDNA assays and genotyping tumor specimens and supports tumor tissue genotyping to confirm undetected results from ctDNA tests. There is no evidence of clinical utility and little evidence of clinical validity of ctDNA assays in early-stage cancer, treatment monitoring, or residual disease detection. There is no evidence of clinical validity and clinical utility to suggest that ctDNA assays are useful for cancer screening, outside of a clinical trial. Given the rapid pace of research, re-evaluation of the literature will shortly be required, along with the development of tools and guidance for clinical practice.en_US
dc.formatPrint-Electronicen_US
dc.format.extent1631 - 1641en_US
dc.languageengen_US
dc.language.isoengen_US
dc.rights.urihttp://www.rioxx.net/licenses/under-embargo-all-rights-reserveden_US
dc.subjectHumansen_US
dc.subjectNeoplasmsen_US
dc.subjectDNA, Neoplasmen_US
dc.subjectBlood Specimen Collectionen_US
dc.subjectSocieties, Medicalen_US
dc.subjectUnited Statesen_US
dc.subjectGenotyping Techniquesen_US
dc.subjectBiomarkers, Tumoren_US
dc.subjectCirculating Tumor DNAen_US
dc.titleCirculating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review.en_US
dc.typeJournal Article
dcterms.dateAccepted2018-05-16en_US
rioxxterms.versionofrecord10.1200/jco.2017.76.8671en_US
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0en_US
rioxxterms.licenseref.startdate2018-06en_US
rioxxterms.typeJournal Article/Reviewen_US
dc.relation.isPartOfJournal of clinical oncology : official journal of the American Society of Clinical Oncologyen_US
pubs.issue16en_US
pubs.notes6 monthsen_US
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Breast Cancer Research
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Breast Cancer Research/Molecular Oncology
pubs.publication-statusPublisheden_US
pubs.volume36en_US
pubs.embargo.terms6 monthsen_US
icr.researchteamMolecular Oncologyen_US
dc.contributor.icrauthorTurner, Nicholasen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record